

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/14/2016; Page 1

	Ascorbic Acid 120 mg, Coenzyme Q ₁₀ 20 mg, CollaSil OSA 200 mg, Zinc Picolinate 47.3 mg Oral Capsules (Powder Blend, 60 × Size #0 Capsules)	FIN	F 007 021
--	--	-----	-----------

Notes: Zinc Picolinate 47.3 mg is equivalent to Zinc 10 mg.

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Ascorbic Acid, USP	7.200	g				
Coenzyme Q ₁₀ (Ubidecarenone), USP	1.200	g				
CollaSil OSA	12.000	g				
Zinc Picolinate	2.838	g				
Medisca CapsuBlend TM -H	TBD			1		
Sodium Chloride, USP	As required		U'	T		

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>	× 1 ·
Light sensitive (protect from lig	tht whenever possible): Ascorbic Acid, Coenzyme Q_{10}
Hygroscopic (protect from mois	sture whenever possible): CollaSil OSA, CapsuBlend-H
Suggested Preparatory Guidelines	
Non-Sterile Preparati	on Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/14/2016; Page 2

	Ascorbic Acid 120 mg, Coenzyme Q ₁₀ 20 mg, CollaSil OSA 200 mg, Zinc Picolinate 47.3 mg Oral Capsules (Powder Blend, 60 × Size #0 Capsules)	FIN	F 007 021
--	--	-----	-----------

SUGGESTED PREPARATION (for 60 Size #0 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Ascorbic Acid, USP §	7.200	g			
Coenzyme Q ₁₀ (Ubidecarenone), USP §	1.200	g			
CollaSil OSA §	12.000	g			
Zinc Picolinate	2.838	g			
Medisca CapsuBlend TM -H §	TBD		0.4		
Sodium Chloride, USP	As required		7 ~		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

Preparatory Instruction						
1.	CapsuBlend TM -H requirements for 60 × Size #0 Capsules					
	A. Calculate the amount of CapsuBlend™-H required for the batch. Refer to attached appendix for details.					
	1.					

2. Powder preparation:

- A. By geometrical addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend:
 - -Ascorbic Acid
 - -Coenzyme Q₁₀ (Ubidecarenone)
 - -Zinc Picolinate
 - -CollaSil OSA
 - -CapsuBlendTM-H (quantity determined in appendix (**I**))

3. **Product transfer:**

Fill each of 60 Size #0 Opaque Capsules with the homogeneous powder blend (Step 2A). Close each capsule tightly.

Clean each capsule by placing the capsules in a container filled with Sodium Chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium Chloride to pass through. Finally, roll the capsules on a cloth-covered surface.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/14/2016; Page 3

	Ascorbic Acid 120 mg, Coenzyme Q ₁₀ 20 mg, CollaSil OSA 200 mg, Zinc Picolinate 47.3 mg Oral Capsules (Powder Blend, 60 × Size #0 Capsules)	FIN	F 007 021
--	--	-----	-----------

4. Validation technique:

The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (G) + 0.387 g together.

5. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").

SUGGESTED PRESENTATION

		ITIATION		-	
Estimated Beyond-Use Date		6 months, as per USP*.	Packagi Requireme		Tightly closed capsule shells and vials.
Auxiliary	1	Use as directed. Do not exceed dose.	d prescribed	4	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.
Labels	2	Keep out of reach of children.	7	5	Cap tightly after use.
	3	Keep in a dry place.		6	Keep at room temperature (20°C – 23°C).
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as decompositions.			nsing container as deemed necessary.		
Patient Instructions	Co	ntact your pharmacist in the event	of adverse read	ction	is.

^{*} The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/14/2016; Page 4

Suggested Formula Ascorbic Acid 120 mg, Coenzyme Q₁₀ 20 mg, CollaSil OSA 200 mg, Zinc Picolinate FIN F 007 021

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition.</i> American Pharmaceutical Association; 2012: 157.
2.	Ascorbic Acid. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1983.
3.	Ubidecarenone. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 2407.
4.	Ascorbic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #819.
5.	Ubiquinones (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #10025.
6.	Ascorbic Acid. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 5 th Edition. American Pharmaceutical Association; 2012: 48.
7.	Ascorbic Acid (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 2598.
8.	Ubidecarenone (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 6870.
9.	USP <795>. <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 617.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/14/2016; Page 1

Ap	pendix							
	Procedure							
1.	1. Capsule filling:							
	a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, triturate the powder first, if required in formulation.							
	P	lug each amount into Step 2, column B						
2.	Volu	me Percent Occupied:						
]	<u>Ingredients</u>	Column A Quantity Required per capsule	Column B Average capsule fill weight		Column C /B x 100 equals ercent filled		
	a. A	Ascorbic Acid	0.120 g	g		%		
	b. C	CollaSil OSA	0.200 g	g		%		
	c. Z	Zinc Picolinate	0.047 g	g		%		
	d. C	apsuBlend™-H	17	g				
	c. T	otal (add column C together)				% (D)		
3.	Calcu	ulate the quantity of CapsuBlend TM -I	H required for the batch:					
	a. Po	ercent of CapsuBlend TM -H required = 1	00% – (D)			% (E)		
	b. Average capsule fill weight of CapsuBlend TM -H (from column B, Step 2d):							
	c. Quantity of CapsuBlend TM -H required per capsule = $[(E) \div 100 \times (F)] - (0.02 \text{ g})^*$ g (G) *[Quantity of Coenzyme Q10 per capsule]							
	d. Total Quantity of CapsuBlend TM -H required for the batch = 60 capsules \times (G) g (H)							
	e. Total quantity of CapsuBlend TM -H plus processing error = (H) \times 1.05-1.09 g (I)							

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.